Eli Lilly's Omvoh shows long-term remission and improved quality of life for ulcerative colitis patients in new trial results ...

Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial ...

Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary ...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...

Herantis Pharma is developing HER-096, a first-in-class drug candidate with the potential to stop the progression of Parkinson’s disease, repair striatal damage and significantly improve both an ...

Earlier this year at the American Society of Clinical Oncology (ASCO) Congress, pharmaphorum spoke with Redwood City, ...

Sustained two-year treatment with tildrakizumab improved the psychological well-being of people with moderate to severe ...

Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific data and carry potential risks such as hepatotoxicity, teratogenicity, or ...

RealTime eClinical Solutions co-authors industry-first guide for sponsor-site collaboration on technology choice. SAN ANTONIO, Oct. 7, 2025 /PRNewswire/ ...

For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater reductions in body weight than placebo.

The firm will use the funds to move its gene therapy for BAG3-associated dilated cardiomyopathy toward the clinic, among other pipeline candidates.

The company expects topline results in 2026 from this group of the basket trial testing the drug plixorafenib as a ...